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Adamczyk).Our previous studies indicated that exogenous a-synuclein (ASN) activates neuronal nitric oxide
(NO) synthase (nNOS) in rat brain slices. The present study, carried out on immortalized hippocam-
pal neuronal cells (HT22), was designed to extend the previous results by showing the molecular
pathway of NO-mediated cell death induced by exogenous ASN. Extracellular ASN (10 lM) was found
to stimulate nitric oxide synthase (NOS) and increase caspase-3 activity in HT22 cells, leading to
poly(ADP-ribose) polymerase (PARP-1) cleavage. The inhibitor of Ca2+-dependent NOS (N-nitro-L-
arginine, 100 lM) prevented ASN-evoked caspase-3 activation and PARP-1 degradation. ASN expo-
sure resulted in apoptotic death of HT22 cells and this effect was reversed by inhibition of NO syn-
thesis and caspase-3 activity. Our results demonstrated that extracellular ASN induces neuronal cell
death by NO-mediated caspase-3 activation.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
a-Synuclein (ASN), a small (140 aa) acidic synaptic protein, is
recognized in various cell types, but mostly it is present in the cen-
tral nervous system, and is especially abundant in presynaptic ter-
minals [1,2]. The function of ASN under normal physiological
conditions as well as its role in neurodegenerative diseases de-
pends on the concentration and the assembly state [3]. Under nor-
mal expression levels ASN is important for synaptic integrity, but
when overexpressed, it has neuropathological effects as exhibited
in Parkinson’s disease (PD) and other synucleinopathies [4–7]. Re-
cent studies emphasized the signiﬁcance of extracellular ASN and
the important role of this pool of ASN in a cascade of cellular events
leading to neuronal dysfunction [8–12]. It was suggested that ASN
could be secreted from cells via exocytosis and could exert cyto-
toxic effect on neighbouring cells [13]. Consistent with this
hypothesis, it was shown that exposure of cultured microglial cellschemical Societies. Published by E
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adamczyk72@gmail.com (A.to exogenous ASN induced their activation [14,15]. More recently,
it was shown that ASN aggregates released from neurons can be
transferred to neighbouring neurons where they form Lewy
body-like inclusions [16], providing mechanistic basis for the
development of Lewy pathology in mesencephalic transplants in
PD patients [17,18]. Our previous data indicated that ASN is liber-
ated from synaptoneurosomes into extracellular space during oxi-
dative stress evoked by FeCl2/ascorbate, hydrogen peroxide, or the
nitric oxide (NO) donor sodium nitroprusside (SNP) [19]. In
addition, extracellular ASN potentiated Ca2+ inﬂux in rat synapto-
neurosomes [20] and stimulated neuronal nitric oxide synthase
(nNOS) activity via the NMDA receptor-mediated pathway [8].
NO liberated by over-activated nNOS could react with O2 to form
peroxynitrite (ONOO), which modulates the function of a variety
of biomolecules including proteins, lipids and DNA. Previously, we
showed that NO could be the important mediator of extracellular
ASN-evoked dopamine transporter alteration and inhibition of
poly(ADP-ribose) polymerase (PARP-1) activity [21,22]. However,
the relationship of NO liberation and cytotoxic mechanisms of
extracellular ASN remains largely unclear.
Here, we report that extracellular ASN stimulates nitric oxide
synthase (NOS) activity and that excessively synthesized NO leads
to caspase-3 activation and concomitant cell death. Therefore,
when neurons are under extracellular ASN stress, NO potentially
acts as a signal molecule inducing death pathway and resultant
apoptosis.lsevier B.V. All rights reserved.
Fig. 1. The effect of ASN on the activity of NOS in HT22 cells. NOS activity was
determined in HT22 cells after 8 h incubation with 10 lM ASN in culture medium
containing 2% fetal bovine serum. Data represent the mean value ± S.E.M. for three
separate experiments, each carried out in triplicate. *P < 0.05 versus control
(Student’s t-test).
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2.1. Cell culture and cell treatment
The studies were carried out using immortalized clonal mouse
hippocampal cell line (HT22). HT22 cells were cultured in 75 cm2
ﬂasks in DMEM supplemented with 10%-heat-inactivated fetal bo-
vine serum (FBS), 1% penicillin/streptomycin (50 U/ml) and 2 mM
glutamine. Cells were maintained at 37 C in a humidiﬁed incuba-
tor containing 5% CO2. Conﬂuent cells were sub-cultured into
35 mm2 dishes and used for experiments at 75–90% conﬂuence.
Prior to treatment, cells were replenished with 2% FBS medium.
Cells were treated with ASN (10 lM) and NO donor, SNP
(500 lM) for 8, 12 and 24 h. Inhibitor of Ca2+-dependent NOS (N-
nitro-L-arginine (NNLA), 100 lM) and caspase-3 inhibitor (Z-
DQMD-FMK, 40 lM) were added 5 min before starting incubation
with ASN. After treatment cells were scraped, washed twice with
ice-cold PBS buffer. The pellet was re-suspended in ice-cold lysis
buffer pH 7.4 (in mM: HEPES 50, CHAPS 5, DTT 5), incubated
20 min at 4 C and then was passed 10 times through 26-gauge
needle. The cell lysate was centrifuged at 14 000g for 15 min.
The supernatant was used for measurement of caspase-3 activity,
and the pellet re-suspended in 25 mM Tris, pH 7.4 was used for
Western Blot analysis of PARP-1.
2.2. Cytotoxicity assay
The effect of ASN treatment on mitochondrial function and cell
survival was analyzed by MTT assay. Equal cell numbers were
cultured on 24-well PEI-coated plate, and after 48 h growth med-
ium was changed to low-serum (2% FBS) medium. After treatment
with investigated substances MTT (0.25 mg/ml) was added and
cells were incubated for 4 h. Then, medium was removed, cells
were dissolved in DMSO and absorbance at 595 nm was
measured.
2.3. Determination of apoptosis
Apoptosis was determined by Hoechst 33258 ﬂuorescent stain-
ing. The cells were examined under a ﬂuorescence microscope
(Olympus BX51, Japan) and photographed with a digital camera
(Olympus DP70, Japan). Cells with typical nuclear morphology (nu-
clear shrinkage, chromatin condensation) were identiﬁed as apop-
totic and counted. The results were expressed as the percentage of
apoptotic cells in whole cell population.
2.4. Determination of the effect of ASN on NOS activity
Cells were washed twice with ice-cold PBS, scraped from the
culture dish and centrifuged shortly (3 min, 1000g). Pellet was
lysed with ice-cold lysis buffer pH 7.2 (in mM: Tris–HCl 50, saccha-
rose 320, EDTA 1, DTT 1, protease inhibitor cocktail). NOS activity
in lysate was assayed by measurement of conversion of radiola-
beled arginine to citrulline using ion-exchange separation, as de-
scribed by [23]. Lysate (ca. 300 lg of protein) was incubated with
the reaction mixture pH 7.4 (in mM: Tris–HCl 50, [14C]L-arginine
(0.1 lCi) 0.1, CaCl2 2, calmodulin 0.001, FAD 0.015, tetrahydrobiop-
terin 0.01, NADPH 1, EDTA 1, DTT 1) in ﬁnal volume of 300 ll for
20 min at 37 C. Reaction was terminated by addition of 1 ml of
stopping buffer pH 5.5 (in mM: Tris–HCl 100, EGTA 10). After cen-
trifugation at 3000g for 10 min, 0.5 ml of supernatant was passed
through 0.5 ml of Dowex™ 50WX-8 column (Na+ form) and [14C]L-
citrulline was eluted with 2  1 ml H2O. The radioactivity of eluted
[14C]L-citrulline was determined by using Bray’s solution scintilla-
tor in LKB Wallac 1409 counter.2.5. Determination of caspase-3 activity
Caspase-3 (EC 3.4.22.56) activity was determined with colori-
metric method by using commercial assay kit (Sigma, St. Louis,
USA). Cells were cultured at 3  106 cells/well, harvested with lysis
buffer, incubated for 20 min at 4 C, disrupted by multiple passes
through a 26-gauge needle and centrifuged at 14 000g for
15 min. The activity of caspase-3 was measured in 5 ll of superna-
tant by using synthetic caspase-3 substrate (Ac-DEVD-pNA, 2 mM)
in reaction buffer in a ﬁnal volume of 100 ll during 4 h incubation
at 37 C. The concentration of pNA, as the product of reaction, was
measured spectrophotometrically at 405 nm. Caspase-3 activity
was calculated as percent of control.
2.6. Western blot analysis of PARP-1
After determination of the total protein content according to
[24], the crude nuclear fraction was mixed with 5 sample buffer
and denatured for 5 min at 95 C. Equal amounts of protein (40 lg)
was loaded onto each line of 7.5% acrylamide gel and resolved by
SDS–PAGE. The proteins were transferred onto nitrocellulose
membrane at 100 V. Membrane was incubated in 1% bovine serum
albumin in PBS with 0.1% Tween 20 for 1 h and exposed overnight
to mouse anti-PARP (1:500) antibody (Santa Cruz). After treatment
for 1 h with the anti-mouse secondary antibody coupled with HRP
(Amersham Biosciences), the protein bands were detected by ECL
reagent (Amersham Biosciences).
2.7. Determination of caspase-3-dependent PARP (Asp 214) cleavage
After treatment, cells were washed twice with ice-cold PBS,
lysed with 150 ll of ice-cold lysis buffer pH 7.5 (in mM: Tris–HCl
20, NaCl 150, Na2EDTA 1, EGTA 1, sodium pyrophosphate 2.5, b-
glycerophosphate 1, Na3VO4 1, phenylmethylsulfonyl ﬂuoride 1,
lg/ml leupeptin and 1% Triton), scraped and sonicated on ice.
The cell lysate was then microcentrifuged for 10 min at 4 C and
supernatant was stored at 80 C before analysis. The level of
cleaved PARP (Asp214) protein was determined by using Path-
Scan Cleaved PARP (Asp 214) Sandwich ELISA kit according to
manufacturer’s protocol (Cell Signaling Technology, Danvers, MA,
USA).
3. Results
To study the role of extracellular ASN in NO liberation in neuro-
nal HT22 cells we analyzed the effect of this protein on the NOS
activity. ASN (10 lM) enhanced total NOS activity by about 60%
after 8 h of treatment (Fig. 1, control value of the NOS activity
Fig. 2. ASN-evoked caspase-3 stimulation and PARP-1 cleavage. (A) Caspase-3
activity was measured spectrophotometrically after 8 h time of incubation of HT22
cells in the absence (control) and presence of ASN (10 lM) or ASN + NNLA (100 lM)
or SNP (500 lM) in culture medium containing 2% fetal bovine serum. Data
represent the mean value ± S.E.M. for 3–8 separate experiments, each carried out in
duplicate. *P < 0.05 versus control, #P < 0.05 versus ASN. (one-way ANOVA followed
by Bonferoni test). (B) The level of 85 kDa product of PARP-1 cleavage was
measured in HT22 cells after 24 h of incubation in the absence (control) and
presence of ASN (10 lM) or ASN + NNLA (100 lM) or SNP (500 lM). Data represent
the mean value ± S.E.M. for four separate experiments, each carried out in triplicate.
*P < 0.05, **P < 0.01 versus control, #P < 0.05 versus ASN (one-way ANOVA followed
by Bonferoni test).
Fig. 3. NOS and caspase-3 inhibition prevented ASN-evoked PARP-1 cleavage. (A)
PARP-1 protein level was measured after 24 h incubation in the absence (control)
and presence of: ASN (10 lM); ASN + NNLA (100 lM); ASN + Z-DQMD-FMK
(40 lM) in culture medium containing 2% fetal bovine serum. Data represent the
mean value ± S.E.M. for ﬁve separate experiments. *P < 0.05 versus control, #P < 0.05
versus ASN (one-way ANOVA followed by Bonferoni test). (B) Representative
Western blot from one typical experiment.
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same time exogenous ASN signiﬁcantly increased activity of
caspase-3 measured with spectrophotometric assay (Fig. 2A, con-
trol value of caspase activity evaluated 0.02 ± 0.002 lmol pNA 
min1 ml1). Concomitantly the ELISA assay revealed the ele-
vated level of caspase-3 cleavage product, the carboxy-terminal
catalytic domain (89 kDa) of PARP-1. Accumulation of cleaved
PARP-1 was detected after 24 h of ASN treatment (Fig. 2B). Similar
effect on caspase-3 activity and PARP-1 degradation was observed
in the presence of NO-donor SNP (500 lM) (Fig. 2A and B). The
inhibitor of Ca2+-dependent NOS (NNLA, 100 lM) prevented ASN-
evoked caspase activation (Fig. 2A) and PARP-1 degradation
(Fig. 2B). To conﬁrm the role of NO and involvement of caspase-3
in PARP-1 cleavage, Western blot analysis was performed. As
shown on Fig. 3 NNLA and Z-DQMD-FMK (40 lM) prevented
ASN-induced degradation of full-length 113 kDa PARP-1 to the
89 kDa product. Subsequently, we analyzed the effect of ASN on
HT22 cells viability. MTT test revealed that extracellular ASN re-
duced cell viability by about 20% after 48 h, but not after 24 h of
treatment (Fig. 4A). Morphological examination of cell nuclei,
stained with DNA-binding ﬂuorochrome Hoechst 33342, showed
that cells exposed to ASN presented typical apoptotic morphology,
including condensation of chromatin and nuclear fragmentation
(Fig. 4B and C). At the end, our results indicated that NOS, as well
as caspase-3 inhibition prevented apoptotic cell death caused by
extracellular ASN (Fig. 4B and C).4. Discussion
ASN is a small presynaptic protein that is released by neurons
into extracellular space, both as a part of its normal cellular pro-
cessing [25] and under oxidative/nitrosative stress and neurode-
generation [19,26]. Excessive amount of ASN released from the
degenerated neurons induces cytotoxic effect through different
mechanisms [27–30]. Previously, we presented that short time
exposure to extracellular ASN in monomeric/oligomeric form acti-
vated NMDA receptor-mediated NO synthesis in rat brain slices [8].
Moreover, NO pool liberated by ASN during the early stage of its
action (30 min incubation) was shown to be involved in alteration
of dopaminergic neurotransmission and in inhibition of PARP-1,
the enzyme involved in DNA repair in response to environmental
stress and maintaining cells viability [21,22].
In the present study, we found that treatment of neuronal HT22
cells with extracellular ASN stimulates NOS activity and induces
NO-dependent caspase-3 activation. Moreover, we showed for
the ﬁrst time that increase of NO level leads to apoptotic neuronal
cells death during exposure to extracellular ASN.
Excessive production of NO, and the concomitant release of
superoxide radical O2 by mitochondria could be responsible for
ONOO formation and neuronal damage caused by ASN [31]. Mul-
tiple lines of evidence indicate that NO-mediated free radical cas-
cade leads to macromolecules oxidation, as well as mitochondrial
and DNA damage, which are common pathogenic mechanisms in-
volved in PD and other synucleinopathies. Pathological post-mor-
tem analysis of PD brains and studies of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated mice suggest that NO
indeed plays an important role in PD [32,33]. It was reported that
nNOS overexpression enhances the susceptibility of SH-SY5Y neu-
roblastoma cells to rotenone treatment [34]. In addition to the
studies on PD-related neurotoxins, it has been demonstrated that
NO evokes structural changes in the ASN protein. Giasson et al.
[35] detected accumulation of nitrated ASN in Lewy bodies of the
PD brain. Thus, nitration of ASN might enhance the formation of
Fig. 4. The effect of ASN on the viability of HT22 cells. (A) The cell viability was
spectrophotometrically determined in HT22 cells by MTT assay after 24 and 48 h of
incubation with 10 lM ASN in culture medium containing 2% fetal bovine serum.
Data represent the mean value ± S.E.M. for four separate experiments, each carried
out in triplicate. **P < 0.01 versus control (one-way ANOVA followed by Bonferoni
test). (B) After 48 h exposure to the 10 lM ASN in culture medium containing 2%
fetal bovine serum nuclei were visualized with Hoechst 33342 and the number of
live and apoptotic cells was counted. Apoptosis is expressed as the percent of
apoptotic cells on the coverslips 48 h after treatment. Data represent the mean
value ± S.E.M. for four separate experiments, each carried out in triplicate.
***P < 0.001 versus control (non-treated) HT22 cells, ###P < 0.001 versus ASN,
##P < 0.01 versus ASN (one-way ANOVA followed by Bonferoni test). (C) Represen-
tative photomicrographs showing Hoechst staining and morphology of control,
ASN-treated, ASN + NNLA (100 lM) and ASN + Z-DQMD-FMK (40 lM)-treated cells.
The arrows indicate nuclei with typical apoptotic features.
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S-nitrosylated by NO, and this modiﬁcation reduces Parkin’s E3 li-
gase activity [36,37].
The precise mechanism of NO action in extracellular ASN-
evoked toxicity was till now not fully understood. Exclusively
Seo et al. [29] indicated that extracellular ASN caused inducible
nitric oxide synthase induction and NO overproduction in rat cor-
tical microglia. Excessively liberated NO and proinﬂammatorymediators exerted signiﬁcant cytotoxic effect on neurons by acti-
vation of Bcl-2 family-related caspase-dependent apoptosis. Here
we present that NOS activation and NO release is a potential
mechanism by which extracellular ASN could be involved in the
activation of caspase-3. Our results are partially consistent with
other studies showing that NOS activation and NO release cause
caspase-3 activation in glial cells treated with L-glutamine [38].
NO donor, SNP also caused caspase-dependent apoptosis of neu-
roblastoma SH-SY5Y cells [39]. Moreover, it was shown that ele-
vation of expression and activity of NOS and caspase-3 activation
are one of the key factors involved in neurodegeneration in PD
and ischemia [40,41]. Other studies also presented that in exper-
imental conditions leading to the increase of intracellular ASN le-
vel, of caspase-3 was activated [42,43]. The presence of active
caspase-3 was detected in degenerated neurons in substantia ni-
gra in animal models of PD [44,45] and in the primary neurons
treated with Ab [46]. This study presented that ASN-induced NO
synthesis and caspase-3 activation is responsible for lowering
PARP-1 protein level due to its cleavage. Our previous data
showed that the NO pool liberated by ASN is partially involved
in decrease of PARP-1 activity [22]. According to the classical
hypothesis, the excessive liberation of NO could initiate the free
radical cascade causing DNA damage that subsequently could
lead to PARP-1 activation [47]. On the contrary, Sidorkina et al.
[48] reported inhibitory effect of NO on PARP-1 activity through
degradation of the zinc ﬁnger motif in this protein. In addition,
results of Pytlowany et al. [49] indicated that SNP strongly de-
creased PARP-1 activity in PC12 cells.
Finally, we found that activation of NO synthesis, which induces
caspase-3 activation and PARP-1 cleavage, results in the apoptosis
of HT22 cells treated with extracellular ASN. Though this is the ﬁrst
study unifying previous data by showing the entire integrated
scheme from excessive NO release, through caspase-3 activation
to apoptotic cell death. In addition to the current study, our previ-
ous results indicated that extracellular ASN leads to mitochondria
dysfunction and caspase-dependent programmed cell death of
PC12 cells [9].
Summarizing, the present data provide the ﬁrst evidence that
NO contributes to extracellular ASN-evoked apoptotic cell death
in the neuronal cells via a caspase-3 signaling cascade suggesting
a new role of ASN in neurodegenerative diseases.
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